Hepatic epithelioid hemangioendothelioma: Long-term results of surgical management
Article first published online: 15 SEP 2008
Copyright © 2008 Wiley-Liss, Inc.
Journal of Surgical Oncology
Volume 98, Issue 6, pages 432–437, 1 November 2008
How to Cite
Mosoia, L., Mabrut, J.-Y., Adham, M., Boillot, O., Ducerf, C., Partensky, C. and Baulieux, J. (2008), Hepatic epithelioid hemangioendothelioma: Long-term results of surgical management. J. Surg. Oncol., 98: 432–437. doi: 10.1002/jso.21132
- Issue published online: 24 OCT 2008
- Article first published online: 15 SEP 2008
- Manuscript Accepted: 2 JUL 2008
- Manuscript Received: 2 JAN 2008
- liver resection;
- liver transplantation
Background and Objectives
Hepatic epithelioid hemangioendothelioma (HEHE) is a rare vascular neoplasm of the liver. Its therapeutic management remains difficult to define in curative intent. The aim of this study was to report long-term results of surgically managed patients.
From 1990 to 2006, nine patients (25–64 years) were retrospectively enrolled in this study. Intrahepatic disease extent was monolobar and bilobar in two and seven patients, respectively. As primary treatment, liver resection (LR) and liver transplantation (LT) were performed in three (two monolobar and one bilobar extent) and six patients, respectively.
Postoperative mortality was nil. During a median follow-up of 117 months, four patients developed intrahepatic and/or extrahepatic recurrence. One resected patient (with bilobar extent) presented with intrahepatic recurrence was secondary treated by LT. At the time of the follow-up, seven out of the nine patients treated (two after LR, and five after LT) were alive and disease-free.
Surgical treatment offers good long-term results in patients suffering from HEHE when LR is tailored to the intrahepatic disease extent: LT has to be considered in patients with bilobar intrahepatic disease whereas LR should be strictly limited to patients presenting with localized and monolobar intrahepatic disease. J. Surg. Oncol. © 2008 Wiley-Liss, Inc.